A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

Recruiting now · Phase 3

Conditions studied: Bladder Cancer

In brief

Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial medicine, can treat locally advanced or metastatic UC that got worse after certain treatments. The goal of this trial is to learn if people who receive sac-TMT live longer than those who receive certain non-platinum chemotherapies.

Key facts

Study ID

NCT07419295

Run by

Merck Sharp & Dohme LLC

People needed

590

Starts

2026-04-23

Expected to finish

2030-04-23

Last updated by the study team

2026-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The main inclusion criteria include but are not limited to the following:
• Has histologically documented locally advanced/metastatic urothelial cancer. Locally advanced disease must not be amenable to resection or radiation with curative intent per investigator assessment
• Has measurable disease per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as assessed by the investigator
• Has received treatment with anti-programmed cell death [ligand] 1 (anti-PD-[L]1) therapy, platinum-based chemotherapy, and enfortumab vedotin (EV)
• Prior therapy with disitamab vedotin (DV) is allowed but will not meet the requirement for prior treatment with EV, except in China, where participants may have received DV instead of EV before study entry
• Has received a maximum of 2 prior lines of therapy
• Has experienced radiographic disease progression on or after the immediate prior line of therapy before study entry
• Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of randomization
• Is eligible to receive at least one of the control arm nonplatinum chemotherapy options (paclitaxel, docetaxel, or vinflunine)
• Is able to provide archival tumor tissue sample or newly obtained biopsy of a tumor lesion not previously irradiated
• If human immunodeficiency virus (HIV) positive, has well-controlled HIV on antiretroviral therapy (ART)
• If hepatitis B surface antigen (HBsAg) positive, has received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and has undetectable HBV viral load
• If history of hepatitis C virus (HCV) infection, has undetectable HCV viral load
• Has adequate organ function

You may not qualify if…

• The main exclusion criteria include but are not limited to the following:
• Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
• Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
• Has a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening
• HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
• Has received prior systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) and has not recovered to grade ≤ 1 or baseline from adverse event (AE) associated with anticancer therapy
• Has received prior therapy with trophoblast cell-surface antigen 2 (TROP2)-targeted antibody drug conjugate (ADC)
• Has received prior therapy with a topoisomerase 1 inhibitor-containing ADC
• Has completed prior external radiotherapy within 6 weeks or stereotactic radiotherapy within 4 weeks of start of study intervention, or has radiation related toxicities, requiring corticosteroids
• Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed
• Has received prior chemotherapy for urothelial cancer with any of the study therapies in the control arm (paclitaxel, docetaxel, and vinflunine)
• Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration
• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
• Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
• Has a current or past history of central nervous system (CNS) metastases and/or carcinomatous meningitis
• Has an active infection requiring systemic therapy other than those permitted per protocol
• Has a history of stem cell/solid organ transplant
• Has not adequately recovered from major surgery, or has ongoing surgical complications

Where it is running

• Memorial Sloan Kettering Cancer Center ( Site 0832) — New York, New York, United States (enrolling)
• WakeMed Raleigh Campus ( Site 0811) — Raleigh, North Carolina, United States (enrolling)
• TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0822) — Cincinnati, Ohio, United States (enrolling)
• The West Clinic, P.C. ( Site 0791) — Germantown, Tennessee, United States (enrolling)
• Thompson Cancer Survival Center ( Site 0803) — Knoxville, Tennessee, United States (enrolling)
• Virginia Oncology Associates (VOA) ( Site 8002) — Norfolk, Virginia, United States (enrolling)
• Asociacion de Beneficencia Hospital Sirio Libanes ( Site 0003) — Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina (enrolling)
• Instituto Alexander Fleming ( Site 0002) — Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina (enrolling)
• Instituto de Oncologia de Rosario ( Site 0005) — Rosario, Santa Fe Province, Argentina (enrolling)
• Macquarie University ( Site 0031) — Macquarie, New South Wales, Australia (enrolling)
• Mater Hospital Brisbane ( Site 0032) — South Brisbane, Queensland, Australia (enrolling)
• Cliniques Universitaires Saint-Luc ( Site 0062) — Brussels, Bruxelles-Capitale, Region de, Belgium (enrolling)
• AZ Maria Middelares ( Site 0063) — Ghent, Oost-Vlaanderen, Belgium (enrolling)
• UZ Gent ( Site 0064) — Ghent, Oost-Vlaanderen, Belgium (enrolling)
• CHC Montlegia Clinic ( Site 0061) — Liège, Belgium (enrolling)
• ICTRIALS Pesquisa e Desenvolvimento ( Site 0107) — Curitiba, Paraná, Brazil (enrolling)
• Hospital Moinhos de Vento ( Site 0102) — Porto Alegre, Rio Grande do Sul, Brazil (enrolling)
• Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0110) — São José do Rio Preto, São Paulo, Brazil (enrolling)
• Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0121) — Québec, Quebec, Canada (enrolling)
• Peking University First Hospital ( Site 0184) — Beijing, Beijing Municipality, China (enrolling)
• The First Affiliated Hospital of Chonqing Medical University ( Site 0197) — Chongqing, Chongqing Municipality, China (enrolling)
• Sun Yat-Sen University Cancer Center ( Site 0183) — Guangzhou, Guangdong, China (enrolling)
• Sun Yat-Sen University Cancer Center ( Site 0188) — Guangzhou, Guangdong, China (enrolling)
• Zhujiang Hospital of Southern Medical University ( Site 0205) — Guangzhou, Guangdong, China (enrolling)
• Munson Medical Center ( Site 0812) — Traverse City, Michigan, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.